Glycated albumin is superior to glycated hemoglobin for glycemic control assessment at an early stage of diabetes treatment: A multicenter, prospective study

详细信息    查看全文

• 作者：Ju-Ming Lu^a ; ^{lujuming301@126.com" class="auth_mail" title="E-mail the corresponding author} ; Li-Nong Ji^b ; ^{jilinong@gmail.com" class="auth_mail" title="E-mail the corresponding author} ; Yu-Feng Li^c ; Quan-Min Li^d ; Shan-Shan Lin^e ; Xiao-Feng Lv^f ; Li Wang^g ; Yuan Xu^h ; Xiao-Hui Guoⁱ ; Qi-Yu Guo^j ; Li Ma^k ; Jin Du^a ; Ying-Li Chen^b ; Cui-Ling Zhao^c ; Qiu-Lan Zhang^d ; Qi-Mei She^e ; Xiu-Min Jiao^f ; Mei-Hua Lu^g ; Rong-Qing Pan^h ; Ying Gaoⁱ
• 关键词：Glycated albumin ; Glycated hemoglobin ; Diabetes ; Oral hypoglycemic agents ; Fasting blood glucose
• 刊名：Journal of Diabetes and its Complications
• 出版年：2016
• 出版时间：November-December 2016
• 年：2016
• 卷：30
• 期：8
• 页码：1609-1613
• 全文大小：406 K

文摘

This study was to determine whether serum glycated albumin (GA) was a better indicator of glycemic control than hemoglobin A1c (HbA1c) when starting a new treatment regimen for type 2 diabetes.

Methods

Newly diagnosed type 2 diabetes patients, or patients who had poor glycemic control with oral hypoglycemic agents, were enrolled at 10 hospitals in Beijing. Serum GA, HbA1c, fasting blood glucose (FBG), and C-peptide were assayed on Days 0, 14, 28, and 91 after treatment.

Results

Four hundred ninety-nine patients were enrolled. Mean FBG, GA and HbA1c decreased significantly in patients at Days 14, 28, and 91. In patients with improved glycemic control, the reduction of GA and HbA1c levels was 10.5 ± 13.3% vs. 5.1 ± 5.4% on Day 14, 16.0 ± 13.4% vs. 9.0 ± 7.0% on Day 28, and 18.0 ± 16.7% vs. 18.3 ± 9.4% on Day 91, respectively, compared with baseline values. Changes in GA on Day 14, 28 and 91 were all closely correlated with changes in HbA1c on Day 91. Change in GA on Day 14 was correlated with treatment effectiveness evaluated by HbA1c on Day 91.

Conclusions

GA may be a useful marker for assessing glycemic control at an early stage of new diabetes treatment and assist in guiding adjustments to treatment and therapy.